ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 226 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $509 | -24.9% | 14,289 | -2.7% | 0.00% | -20.0% |
Q2 2023 | $678 | +26.7% | 14,687 | +10.1% | 0.01% | 0.0% |
Q1 2023 | $535 | -21.3% | 13,337 | -9.1% | 0.01% | -16.7% |
Q4 2022 | $680 | -99.9% | 14,673 | +1.7% | 0.01% | 0.0% |
Q3 2022 | $597,000 | -29.9% | 14,422 | +0.9% | 0.01% | -25.0% |
Q2 2022 | $852,000 | -17.2% | 14,288 | +0.8% | 0.01% | 0.0% |
Q1 2022 | $1,029,000 | -53.6% | 14,171 | -46.3% | 0.01% | 0.0% |
Q4 2021 | $2,220,000 | +110.8% | 26,406 | +126.1% | 0.01% | -11.1% |
Q3 2021 | $1,053,000 | -10.7% | 11,679 | -5.6% | 0.01% | 0.0% |
Q2 2021 | $1,179,000 | +14.5% | 12,367 | +36.7% | 0.01% | -76.9% |
Q1 2021 | $1,030,000 | -23.9% | 9,049 | -7.4% | 0.04% | -23.5% |
Q4 2020 | $1,353,000 | +84.1% | 9,773 | +9.3% | 0.05% | +59.4% |
Q3 2020 | $735,000 | +3.5% | 8,944 | -1.4% | 0.03% | -3.0% |
Q2 2020 | $710,000 | +60.3% | 9,072 | -9.1% | 0.03% | +200.0% |
Q1 2020 | $443,000 | -2.4% | 9,981 | -6.2% | 0.01% | +37.5% |
Q4 2019 | $454,000 | +9.7% | 10,641 | +10.0% | 0.01% | -11.1% |
Q3 2019 | $414,000 | -33.4% | 9,671 | -1.2% | 0.01% | -40.0% |
Q2 2019 | $622,000 | +11.7% | 9,790 | +21.9% | 0.02% | +15.4% |
Q1 2019 | $557,000 | +86.3% | 8,029 | +16.6% | 0.01% | +62.5% |
Q4 2018 | $299,000 | +42.4% | 6,887 | +150.9% | 0.01% | +60.0% |
Q3 2018 | $210,000 | -62.0% | 2,745 | -61.7% | 0.01% | -61.5% |
Q2 2018 | $552,000 | +82.2% | 7,176 | +20.8% | 0.01% | +62.5% |
Q1 2018 | $303,000 | +21.2% | 5,940 | +10.3% | 0.01% | +14.3% |
Q4 2017 | $250,000 | -6.7% | 5,387 | +7.0% | 0.01% | -12.5% |
Q3 2017 | $268,000 | -13.3% | 5,036 | +1.1% | 0.01% | -20.0% |
Q2 2017 | $309,000 | -1.6% | 4,980 | +7.6% | 0.01% | -37.5% |
Q1 2017 | $314,000 | +1.0% | 4,628 | +4.6% | 0.02% | +14.3% |
Q4 2016 | $311,000 | +15.2% | 4,426 | +16.2% | 0.01% | -12.5% |
Q3 2016 | $270,000 | +3.8% | 3,810 | +0.1% | 0.02% | +6.7% |
Q2 2016 | $260,000 | +1.6% | 3,805 | -6.0% | 0.02% | -40.0% |
Q1 2016 | $256,000 | -38.2% | 4,047 | +9.6% | 0.02% | -51.0% |
Q4 2015 | $414,000 | +6.7% | 3,693 | -8.3% | 0.05% | +24.4% |
Q3 2015 | $388,000 | +2.1% | 4,027 | +8.4% | 0.04% | +10.8% |
Q2 2015 | $380,000 | – | 3,714 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |